Bristol-Myers Squibb

BMS launches digital Advocacy Exchange for patient groups affected by COVID-19
BMS launches digital Advocacy Exchange for patient groups affected by COVID-19
Pharmaforum
Bristol-Myers Squibb
GRYT Health
COVID-19
pandemic
patients
digital health
Flag link:
Third-quarter events to watch for large drug makers
Third-quarter events to watch for large drug makers
EP Vantage
Biogen
aducanumab
Sanofi
THOR-707
Bristol-Myers Squibb
pegbelfermin
Eli Lilly
FDA
Flag link:
After Celgene deal, BMS shoots up pharma market cap rankings
After Celgene deal, BMS shoots up pharma market cap rankings
Pharmaforum
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Endpoints
Merck
Keytruda
Bristol-Myers Squibb
FDA
biomarkers
accelerated approvals
cancer
TMB
Flag link:
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Pharmaceutical Business Review
Clovis Oncology
clinical trials
Rubraca
ovarian cancer
Opdivo
Bristol-Myers Squibb
Flag link:
Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer
Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer
Pharmaceutical Business Review
UbiVac
Bristol-Myers Squibb
clinical trials
triple negative breast cancer
DPV-001
Flag link:
Bristol's Celgene merger sees it bounce Jounce drug pact
Bristol's Celgene merger sees it bounce Jounce drug pact
Fierce Biotech
Bristol-Myers Squibb
Celgene
Jounce Therapeutics
M&A
immuno-oncology
Flag link:
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
Pharmaforum
ASCO 2020
Amgen
AstraZeneca
Bristol-Myers Squibb
cancer
CAR-T
COVID-19
Keytruda
Kyprolis
Tagrisso
Flag link:
FDA approval tracker: several early decisions in May
FDA approval tracker: several early decisions in May
EP Vantage
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
Flag link:
BMS' Recently Approved MS Drug Shows Promise in Ulcerative Colitis Study
BMS' Recently Approved MS Drug Shows Promise in Ulcerative Colitis Study
BioSpace
Bristol-Myers Squibb
Zeposia
ozanimod
ulcerative colitis
Flag link:
Bristol Myers Squibb's Zeposia launches into crowded MS market
Bristol Myers Squibb's Zeposia launches into crowded MS market
Fierce Pharma
Bristol-Myers Squibb
Celgene
Zeposia
drug launches
MS
multiple sclerosis
Flag link:
IPOs abound in the time of coronavirus, as Forma Therapeutics pencils in $150M Nasdaq debut
IPOs abound in the time of coronavirus, as Forma Therapeutics pencils in $150M Nasdaq debut
Endpoints
IPOs
NASDAQ
Forma Therapeutics
Bristol-Myers Squibb
COVID-19
Flag link:
After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO
After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO
Xconomy
cancer
IPOs
Repare Therapeutics
Bristol-Myers Squibb
Flag link:
Q32 Bio Launches with $46 Million and IL-7 Inhibitor Licensed from BMS
Q32 Bio Launches with $46 Million and IL-7 Inhibitor Licensed from BMS
BioSpace
Q32 Bio
Bristol-Myers Squibb
Flag link:
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
Pharmaceutical Business Review
Bristol-Myers Squibb
Opdvio
Yervoy
metastatic non-small cell lung cancer
Flag link:
Bristol Myers snags Pomalyst green light in rare AIDS-related skin lesions
Bristol Myers snags Pomalyst green light in rare AIDS-related skin lesions
Fierce Pharma
Bristol-Myers Squibb
Pomalyst
AIDS
FDA
Kaposi's Sarcoma
Flag link:
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Flag link:
ASCO 2020 – first-line lung cancer focus
ASCO 2020 – first-line lung cancer focus
EP Vantage
Roche
Merck
Bristol-Myers Squibb
ASCO 2020
lung cancer
Keytruda
tiragolumab
Opdivo
Yervoy
Flag link:
Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline
Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline
Motley Fool
Bristol-Myers Squibb
Bluebird Bio
refusal to file letter
FDA
ide-cel
Flag link:
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Bluebird Bio
Flag link:

Pages